RSVPreF3 OA investigational vaccine for respiratory syncytial virus infections

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 1 Feb 2021: Trial registered, NCT04732871
  2. 15 Feb 2021: Trial started, NCT04732871

The trials

NCT04732871: Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

State
Under way
Phase
Phase 3
People
1,720 taking part
Started
15 Feb 2021
Primary completion
6 Jun 2022
Arms
RSV_annual Group, RSV_Flexible revaccination Group, RSV_1dose Group
Results
Posted on the registry
  1. 1 Feb 2021: Trial registered
  2. 15 Feb 2021: Trial started
  3. 21 Dec 2023: Trial results posted

Posted results

The numbers the trial's sponsor posted to the registry, as written there. The registry record says what each measure runs from and to.

Humoral Immune Response in Terms of Respiratory Syncytial Virus (RSV)-A Neutralizing Antibody Geometric Mean Titers (GMTs) at Day 1

Primary outcome · Geometric mean, Titers (ED60) · At Day 1

GroupAnalysedValue
RSV_annual342832.4 (95% Confidence Interval 763.4 to 907.7)
RSV_flexible Revaccination321864.9 (95% Confidence Interval 790.6 to 946.1)
RSV_1dose319896.8 (95% Confidence Interval 815.9 to 985.8)

Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Day 31

Primary outcome · Geometric mean, Titers (ED60) · At Day 31

GroupAnalysedValue
RSV_annual3288827.2 (95% Confidence Interval 7905 to 9857)
RSV_flexible Revaccination3008906.6 (95% Confidence Interval 7972.3 to 9950.3)
RSV_1dose3099585.6 (95% Confidence Interval 8448.8 to 10875.5)

Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 6

Primary outcome · Geometric mean, Titers (ED60) · At Month 6

GroupAnalysedValue
RSV_annual3193465.2 (95% Confidence Interval 3140.9 to 3823)
RSV_flexible Revaccination2943600.1 (95% Confidence Interval 3242.2 to 3997.5)
RSV_1dose3114223.1 (95% Confidence Interval 3795.3 to 4699)

Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 12

Primary outcome · Geometric mean, Titers (ED60) · At Month 12

GroupAnalysedValue
RSV_annual2842529.9 (95% Confidence Interval 2274.5 to 2814)
RSV_flexible Revaccination2912695.7 (95% Confidence Interval 2421.4 to 3001)
RSV_1dose2962800.1 (95% Confidence Interval 2501.6 to 3134.3)

Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Day 1

Primary outcome · Geometric mean, Titers (ED60) · At Day 1

GroupAnalysedValue
RSV_annual3421138.7 (95% Confidence Interval 1046.2 to 1239.3)
RSV_flexible Revaccination3211325.9 (95% Confidence Interval 1206.9 to 1456.6)
RSV_1dose3201258.7 (95% Confidence Interval 1142 to 1387.4)

Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Day 31

Primary outcome · Geometric mean, Titers (ED60) · At Day 31

GroupAnalysedValue
RSV_annual3289219.7 (95% Confidence Interval 8368.7 to 10157.3)
RSV_flexible Revaccination3009955.2 (95% Confidence Interval 9002.1 to 11009.3)
RSV_1dose3099756.1 (95% Confidence Interval 8785.4 to 10834)

Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 6

Primary outcome · Geometric mean, Titers (ED60) · At Month 6

GroupAnalysedValue
RSV_annual3193886.4 (95% Confidence Interval 3563.5 to 4238.6)
RSV_flexible Revaccination2944484.6 (95% Confidence Interval 4063.8 to 4949)
RSV_1dose3114570.6 (95% Confidence Interval 4152 to 5031.4)

Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 12

Primary outcome · Geometric mean, Titers (ED60) · At Month 12

GroupAnalysedValue
RSV_annual2842671.4 (95% Confidence Interval 2433.3 to 2932.9)
RSV_flexible Revaccination2913015.4 (95% Confidence Interval 2737.9 to 3321)
RSV_1dose2962977.1 (95% Confidence Interval 2669.6 to 3320)

Humoral Immune Response in Terms of RSVPreF3 Immunoglobulin G (IgG) Antibody Geometric Mean Concentrations (GMCs) at Day 1

Secondary outcome · Geometric mean, ELU/mL · At Day 1

GroupAnalysedValue
RSV_annual3427334.7 (95% Confidence Interval 6868.3 to 7832.8)
RSV_flexible Revaccination3207437.1 (95% Confidence Interval 6948.6 to 7959.9)
RSV_1dose3207759 (95% Confidence Interval 7212.5 to 8346.8)

Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Day 31

Secondary outcome · Geometric mean, ELU/mL · At Day 31

GroupAnalysedValue
RSV_annual32886929.7 (95% Confidence Interval 80662.7 to 93683.6)
RSV_flexible Revaccination30092664.7 (95% Confidence Interval 86050.1 to 99787.8)
RSV_1dose30994249.4 (95% Confidence Interval 87660.7 to 101333.3)

Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 6

Secondary outcome · Geometric mean, ELU/mL · At Month 6

GroupAnalysedValue
RSV_annual31933855.9 (95% Confidence Interval 31405.3 to 36497.7)
RSV_flexible Revaccination29435193.5 (95% Confidence Interval 32623.6 to 37965.9)
RSV_1dose31136525.7 (95% Confidence Interval 33938 to 39310.7)

Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 12

Secondary outcome · Geometric mean, ELU/mL · At Month 12

GroupAnalysedValue
RSV_annual28424733.5 (95% Confidence Interval 22994.3 to 26604.2)
RSV_flexible Revaccination29126484.1 (95% Confidence Interval 24651.7 to 28452.8)
RSV_1dose29627360.3 (95% Confidence Interval 25476.7 to 29383)

Cell-Mediated Immunity (CMI) Response in Terms of Frequency of RSVPreF3-specific Cluster of Differentiation CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 1

Secondary outcome · Median, CD4 atl2_7m/ million of CD4+ cells · At Day 1

GroupAnalysedValue
RSV_annual287202 (Inter-Quartile Range 83 to 376)
RSV_flexible Revaccination93143 (Inter-Quartile Range 26 to 294)
RSV_1dose95171 (Inter-Quartile Range 65 to 385)

CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 1

Secondary outcome · Median, CD8 atl2_7m/ million of CD8+ cells · At Day 1

GroupAnalysedValue
RSV_annual28733 (Inter-Quartile Range 1 to 110)
RSV_flexible Revaccination9332 (Inter-Quartile Range 1 to 103)
RSV_1dose952 (Inter-Quartile Range 1 to 107)

CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 31

Secondary outcome · Median, CD4 atl2_7m/ million of CD4+ cells · At Day 31

GroupAnalysedValue
RSV_annual2451310 (Inter-Quartile Range 813 to 2155)
RSV_flexible Revaccination811292.5 (Inter-Quartile Range 820.5 to 2254)
RSV_1dose841570 (Inter-Quartile Range 876 to 1971)

CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 31

Secondary outcome · Median, CD8 atl2_7m/ million of CD8+ cells · At Day 31

GroupAnalysedValue
RSV_annual24526 (Inter-Quartile Range 1 to 129)
RSV_flexible Revaccination8158 (Inter-Quartile Range 1 to 143)
RSV_1dose845 (Inter-Quartile Range 1 to 101)

CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 6

Secondary outcome · Median, CD4 atl2_7m/ million of CD4+ cells · At Month 6

GroupAnalysedValue
RSV_annual263662 (Inter-Quartile Range 428 to 1026)
RSV_flexible Revaccination87644 (Inter-Quartile Range 442 to 1100)
RSV_1dose86695 (Inter-Quartile Range 427 to 1131)

CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 6

Secondary outcome · Median, CD8 atl2_7m/ million of CD8+ cells · At Month 6

GroupAnalysedValue
RSV_annual24838 (Inter-Quartile Range 1 to 113)
RSV_flexible Revaccination8824.5 (Inter-Quartile Range 1 to 103.5)
RSV_1dose8526 (Inter-Quartile Range 1 to 87)

CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 12

Secondary outcome · Median, CD4 atl2_7m/ million of CD4+ cells · At Month 12

GroupAnalysedValue
RSV_annual257564 (Inter-Quartile Range 348 to 898)
RSV_flexible Revaccination94525 (Inter-Quartile Range 345 to 818)
RSV_1dose92671 (Inter-Quartile Range 374.5 to 1072.5)

CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 12

Secondary outcome · Median, CD8 atl2_7m/ million of CD8+ cells · At Month 12

GroupAnalysedValue
RSV_annual2571 (Inter-Quartile Range 1 to 81)
RSV_flexible Revaccination9418 (Inter-Quartile Range 1 to 108)
RSV_1dose9222 (Inter-Quartile Range 1 to 104)

Number of Participants With at Least One Solicited Administration-site Event Following Vaccination at Day 1

Secondary outcome · Number of participants · During the 4-day follow up period after first vaccination (vaccine administered on Day 1)

GroupAnalysedValue
RSV_annual
Erythema
98999
RSV_flexible Revaccination
Erythema
32838
RSV_1dose
Erythema
32822
RSV_annual
Pain
989595
RSV_flexible Revaccination
Pain
328201
RSV_1dose
Pain
328200
RSV_annual
Swelling
98975
RSV_flexible Revaccination
Swelling
32833
RSV_1dose
Swelling
32816

Number of Participants With at Least One Solicited Systemic Event Following Vaccination at Day 1

Secondary outcome · Number of participants · During the 4-day follow up period after vaccination (vaccine administered on Day 1)

GroupAnalysedValue
RSV_annual
Arthralgia
989157
RSV_flexible Revaccination
Arthralgia
32849
RSV_1dose
Arthralgia
32949
RSV_annual
Fatigue
989307
RSV_flexible Revaccination
Fatigue
328100
RSV_1dose
Fatigue
329110
RSV_annual
Fever
98913
RSV_flexible Revaccination
Fever
3285
RSV_1dose
Fever
3297
RSV_annual
Headache
989187
RSV_flexible Revaccination
Headache
32870
RSV_1dose
Headache
32979
RSV_annual
Myalgia
989336
RSV_flexible Revaccination
Myalgia
328107
RSV_1dose
Myalgia
329109

Number of Participants With Any Unsolicited Adverse Events (AEs) Following Vaccination at Day 1

Secondary outcome · Number of participants · During the 30-day follow up period after vaccination (vaccine administered on Day 1)

GroupAnalysedValue
RSV_annual993125
RSV_flexible Revaccination32945
RSV_1dose33155

Number of Participants With Serious Adverse Events (SAE) Following Vaccination at Day 1

Secondary outcome · Number of participants · From first vaccination (Day 1) up to 6 months post-Dose 1 (Month 6)

GroupAnalysedValue
RSV_annual99336
RSV_flexible Revaccination32916
RSV_1dose33115

Number of Participants Reporting Any Potential Immune-mediated Disease (pIMD) Following Vaccination at Day 1

Secondary outcome · Number of participants · From first vaccination (Day 1) up to 6 months post-Dose 1 (Month 6)

GroupAnalysedValue
RSV_annual9930
RSV_flexible Revaccination3291
RSV_1dose3310

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.